Mellor R, Kearnes M, Lancaster K, McLauchlan L, Ritter A. Established tables and emergent huddles: exploring the processes of participation associated with the policy changes to opioid pharmacotherapy treatment in Australia in the context of COVID-19. Contemp Drug Probl. 2022 Sep 8;49(4):385-404. doi: 10.1177/00914509221123001
Harold S, Dienes K. The influence of ethnicity and nationality on cortisol reactivity to an acute laboratory stressor, with and without partner support. Poster presented at the American Psychosomatic Society 77th Annual Scientific Meeting; March 2019. Vancouver, Canada. [abstract] Psychosom Med. 2019 May; 81(4):A71. doi: 10.1097/PSY.0000000000000699
Lairson DR, Parikh RC, Cormier JN, Wenyaw C, Du XL. Cost-utility analysis of treatments for advanced non-small cell lung cancer. Am J Pharm Benefits. 2015 Nov;7(6):271-9.
Lopes M, Chulikavit M, Parikh R, Stern L, Liu Z, Rogerio J. Budget impact of everolimus in treating metastatic renal cell carcinoma. Am J Pharm Benefits. 2012;4(Special Issue):sp41-8.